2. Search Result
Search Result
Results for "

human CDK6

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Natural
Products

6

Recombinant Proteins

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0819
    Raddeanin A
    1 Publications Verification

    		 Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK Neurological Disease Inflammation/Immunology Cancer
    Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .
    Raddeanin A
  • HY-148214
    CDK2/4/6-IN-2

    		CDK Cancer
    CDK2/4/6-IN-2 is a selective CDK2/4/6 inhibitor with IC50 values <1 μM. CDK2/4/6-IN-2 inhibits cells proliferation and phosphorylation of retinoblastoma protein at Ser807/811 in breast cancer cells. CDK2/4/6-IN-2 can be used for the research of cancer, such as breast cancer .
    CDK2/4/6-IN-2
  • HY-RS02392
    CDK6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) CDK Others

    CDK6 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK6 Human Pre-designed siRNA Set A
    CDK6 Human Pre-designed siRNA Set A
  • HY-E70687
    CDK6/CycD2 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CDK6 is a cell-cycle kinases that regulate exit from the G1 phase of the cell cycle. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. CDK6/CycD2 Recombinant Human Active Protein Kinase is an ortholog of CDK6 .
    CDK6/CycD2 Recombinant Human Active Protein Kinase
  • HY-E70688
    CDK6/CycD3 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CDK6 is a cell-cycle kinases that regulate exit from the G1 phase of the cell cycle. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. CDK6/CycD3 Recombinant Human Active Protein Kinase is an ortholog of CDK6 .
    CDK6/CycD3 Recombinant Human Active Protein Kinase
  • HY-E70686
    CDK6/CycD1 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CDK6 is a cell-cycle kinases that regulate exit from the G1 phase of the cell cycle. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. CDK6/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK6 .
    CDK6/CycD1 Recombinant Human Active Protein Kinase
  • HY-116204
    SKLB70326

    		Caspase CDK Apoptosis Bcl-2 Family PARP Others
    SKLB70326 is a small molecule inhibitor of cell cycle progression that induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. SKLB70326 is involved in downregulating cyclin-dependent kinase (CDK) 2, CDK4, and CDK6, while also activating PARP, caspase-3, caspase-9, and Bax, and downregulating Bcl-2.
    SKLB70326
  • HY-182036
    KWZL-7f15

    		Epigenetic Reader Domain Cancer
    KWZL-7f15 (compound 7f15) is a dual CDK6/BET inhibitor with an IC50 of 31.81 nM against human CDK6. KWZL-7f15 inhibits the CDK6-RB axis and the BRD4-Myc axis. KWZL-7f15 exhibits antiproliferative activity against triple-negative breast cancer cells. KWZL-7f15 shows antitumor activity in xenograft mouse models without significant adverse effects. KWZL-7f15 can be used in studies related to triple-negative breast cancer .
    KWZL-7f15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: